Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty
Goldman Sachs downgraded Dynavax Technologies Corporation (NASDAQ:DVAX) reflecting updated views and recent competitive ...
Dynavax stock drops following Goldman Sachs downgrade
Goldman Sachs analyst Paul Choi downgraded the stock from "Neutral" to "Sell," setting a price target of $12, which is ...
Goldman Sachs cuts Dynavax stock rating to sell, target to $12
Goldman Sachs downgraded Dynavax Technologies Corporation (NASDAQ:DVAX) stock from Neutral to Sell, adjusting the price target downward to $12.00 from the previous $15.00. According to InvestingPro ...
Dynavax downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs downgraded Dynavax (DVAX) to Sell from Neutral with a price target of $12, down from $15. The evolving competitive landscape in ...
Dynavax appoints new principal accounting officer
Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company with a market capitalization of $1.73 billion and strong financial health according to InvestingPro analysis, announced a ...
Dynavax Technologies: Time To Refocus On Former Cash Cow CpG1018
Dynavax should take a leaf from its vaccine maker peer, Novavax, and work to monetize its CpG1018 adjuvant. Learn more about ...